Læknablaðið : fylgirit - 01.05.1978, Side 64

Læknablaðið : fylgirit - 01.05.1978, Side 64
PLASMA NAPROXEN pg/ml PLASMA NAPROXEN •----• PLASMA DES-METHYL-NAPROXEN O—-O (jg/ml 2 4 6 8 10 HOURS AFTER INGESTION Fig. 2 The biological half timc of naproxen, calculated from the 4 hour and the 8 hour values in three uremic patients after 250 mg of naproxen (single dose). Fig. 1 Plasma levels of naproxen and 6-des- methyl naproxen in patient R.O. after 250 mg of naproxen as a single dose. was 26 ug/ml 12 hours after dose end 44 ug/ml 6 hours after dose. The expected values (2) should have been higher, 40 ug/ml and 55 ug/ml respectively. Results in patient M.J. (one sample lost and a last sample drawn 24 hours after last dose) is shown separately in Table II. High values of 6-des-methyl naproxen are still present 24 hours after the last dose of napraxen. Side effects. No side effects were experienced by those four uremic patients obtaining napraxen 250 mg x 2 for 5-8 days. One of the patients who had osteo-arthritic symptoms claimed to have been improved. Discussion: The presented pilot study, though dealing with only a small number of uremic subjects, seems to permit the conclusion that naproxen itself is not accumulated in plasma in patients with renal failure although its main metaboiite, 6-des- methyl naproxen is accumulated in such patients. In fact surprisingly low plasma values of naproxen was found in patients with renal insufficiency. As shown in Fig. 2 this could be due to a shorter biological half-time for the drug in uremia. However, as shown in Table m, other drugs were given to the investigated patients; drugs not unlikely to have disturbed the gastrointestinal absorption of naproxen (aluminiumhydroxide), interfered with its binding to plasma protein (dicumarol, digoxin, dicloxa- cillin) or to have disturbed the chromatographic analysis. The reversed liquid chromatography method used in the present study is still under development and the analysis of samples from uremic patients offered some difficulties not encountered in healthy subjects, particularly as regards the determination of 6-des-methyI naproxen. It remains to determine to which extent these problems were due to retained substances connected with uremia per se or 62
Side 1
Side 2
Side 3
Side 4
Side 5
Side 6
Side 7
Side 8
Side 9
Side 10
Side 11
Side 12
Side 13
Side 14
Side 15
Side 16
Side 17
Side 18
Side 19
Side 20
Side 21
Side 22
Side 23
Side 24
Side 25
Side 26
Side 27
Side 28
Side 29
Side 30
Side 31
Side 32
Side 33
Side 34
Side 35
Side 36
Side 37
Side 38
Side 39
Side 40
Side 41
Side 42
Side 43
Side 44
Side 45
Side 46
Side 47
Side 48
Side 49
Side 50
Side 51
Side 52
Side 53
Side 54
Side 55
Side 56
Side 57
Side 58
Side 59
Side 60
Side 61
Side 62
Side 63
Side 64
Side 65
Side 66
Side 67
Side 68
Side 69
Side 70
Side 71
Side 72
Side 73
Side 74
Side 75
Side 76
Side 77
Side 78
Side 79
Side 80
Side 81
Side 82
Side 83
Side 84
Side 85
Side 86
Side 87
Side 88
Side 89
Side 90
Side 91
Side 92
Side 93
Side 94
Side 95
Side 96
Side 97
Side 98
Side 99
Side 100
Side 101
Side 102
Side 103
Side 104
Side 105
Side 106
Side 107
Side 108
Side 109
Side 110
Side 111
Side 112
Side 113
Side 114
Side 115
Side 116
Side 117
Side 118
Side 119
Side 120
Side 121
Side 122
Side 123
Side 124
Side 125
Side 126
Side 127
Side 128
Side 129
Side 130
Side 131
Side 132
Side 133
Side 134
Side 135
Side 136
Side 137
Side 138
Side 139
Side 140
Side 141
Side 142
Side 143
Side 144
Side 145
Side 146
Side 147
Side 148
Side 149
Side 150
Side 151
Side 152
Side 153
Side 154
Side 155
Side 156
Side 157
Side 158

x

Læknablaðið : fylgirit

Direkte link

Hvis du vil linke til denne avis/magasin, skal du bruge disse links:

Link til denne avis/magasin: Læknablaðið : fylgirit
https://timarit.is/publication/991

Link til dette eksemplar:

Link til denne side:

Link til denne artikel:

Venligst ikke link direkte til billeder eller PDfs på Timarit.is, da sådanne webadresser kan ændres uden advarsel. Brug venligst de angivne webadresser for at linke til sitet.